title: Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
abstract: Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the American Academy of Dermatology Psoriasis Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients with psoriasis and psoriatic arthritis. In this sixth and final section of the Psoriasis Guidelines of Care, we will present cases to illustrate how to practically use these guidelines in specific clinical scenarios. We will describe the approach to treating patients with psoriasis across the entire spectrum of this fascinating disease from mild to moderate to severe, with and without psoriatic arthritis, based on the 5 prior published guidelines. Although specific therapeutic recommendations are given for each of the cases presented, it is important that treatment be tailored to meet individual patients' needs. In addition, we will update the prior 5 guidelines and address gaps in research and care that currently exist, while making suggestions for further studies that could be performed to help address these limitations in our knowledge base.
authors.affiliation: Psoriasis Research Center, Baylor University Medical Center, Dallas, Texas, USA.
authors.forename: Alan
authors.initials: A
authors.lastname: Menter
authors.forename: Neil J
authors.initials: NJ
authors.lastname: Korman
authors.forename: Craig A
authors.initials: CA
authors.lastname: Elmets
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gelfand
authors.forename: Kenneth B
authors.initials: KB
authors.lastname: Gordon
authors.forename: Alice
authors.initials: A
authors.lastname: Gottlieb
authors.forename: John Y M
authors.initials: JY
authors.lastname: Koo
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
authors.forename: Henry W
authors.initials: HW
authors.lastname: Lim
authors.forename: Abby S
authors.initials: AS
authors.lastname: Van Voorhees
authors.forename: Karl R
authors.initials: KR
authors.lastname: Beutner
authors.forename: Caitriona
authors.initials: C
authors.lastname: Ryan
authors.forename: Reva
authors.initials: R
authors.lastname: Bhushan
mesh_terms: D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000628:therapy*; D019090:Case Management; D003131:Combined Modality Therapy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010789:Phototherapy / Q000379:methods; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000175:diagnosis / Q000628:therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents